1. Home
  2. RGLS vs SERV Comparison

RGLS vs SERV Comparison

Compare RGLS & SERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGLS
  • SERV
  • Stock Information
  • Founded
  • RGLS 2007
  • SERV 2017
  • Country
  • RGLS United States
  • SERV United States
  • Employees
  • RGLS N/A
  • SERV N/A
  • Industry
  • RGLS Biotechnology: Pharmaceutical Preparations
  • SERV Industrial Specialties
  • Sector
  • RGLS Health Care
  • SERV Consumer Discretionary
  • Exchange
  • RGLS Nasdaq
  • SERV Nasdaq
  • Market Cap
  • RGLS 102.1M
  • SERV 964.9M
  • IPO Year
  • RGLS 2012
  • SERV N/A
  • Fundamental
  • Price
  • RGLS $1.23
  • SERV $16.41
  • Analyst Decision
  • RGLS Strong Buy
  • SERV Strong Buy
  • Analyst Count
  • RGLS 6
  • SERV 3
  • Target Price
  • RGLS $10.33
  • SERV $14.67
  • AVG Volume (30 Days)
  • RGLS 281.3K
  • SERV 13.3M
  • Earning Date
  • RGLS 11-07-2024
  • SERV 02-15-2025
  • Dividend Yield
  • RGLS N/A
  • SERV N/A
  • EPS Growth
  • RGLS N/A
  • SERV N/A
  • EPS
  • RGLS N/A
  • SERV N/A
  • Revenue
  • RGLS N/A
  • SERV $1,679,360.00
  • Revenue This Year
  • RGLS N/A
  • SERV $836.66
  • Revenue Next Year
  • RGLS N/A
  • SERV $598.41
  • P/E Ratio
  • RGLS N/A
  • SERV N/A
  • Revenue Growth
  • RGLS N/A
  • SERV 692.32
  • 52 Week Low
  • RGLS $1.08
  • SERV $1.77
  • 52 Week High
  • RGLS $3.79
  • SERV $30.00
  • Technical
  • Relative Strength Index (RSI)
  • RGLS 30.55
  • SERV N/A
  • Support Level
  • RGLS $1.49
  • SERV N/A
  • Resistance Level
  • RGLS $1.64
  • SERV N/A
  • Average True Range (ATR)
  • RGLS 0.11
  • SERV 0.00
  • MACD
  • RGLS -0.04
  • SERV 0.00
  • Stochastic Oscillator
  • RGLS 11.68
  • SERV 0.00

About RGLS Regulus Therapeutics Inc.

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

About SERV Serve Robotics Inc. Common Stock

Serve Robotics Inc is developing next-generation robots for last-mile delivery services. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an advanced, AI-robotics mobility platform, with last-mile delivery in cities as its first application.

Share on Social Networks: